Listed

Mineralys Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2025

Filed with the SEC on May 12, 2025 and accepted by EDGAR at May 12, 2025, 17:31 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2025-01-01 to 2025-03-31$37.9mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2025-01-01 to 2025-03-31−$44.4mus-gaap:OperatingIncomeLoss
Net income3 months2025-01-01 to 2025-03-31−$42.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-01-01 to 2025-03-31−$0.79us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-01-01 to 2025-03-31−$0.79us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-01-01 to 2025-03-3153,163,551 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2025-01-01 to 2025-03-31−$45.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2025-01-01 to 2025-03-31$0us-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2025-03-31$165.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-03-31$354.5mus-gaap:AssetsCurrent
Total assetsAt period end2025-03-31$354.9mus-gaap:Assets
Current liabilitiesAt period end2025-03-31$13.4mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2025-03-31$341.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001933414-25-000058. Last ingested by Listed: Nov 4, 2026, 19:22 ET. Listed shows no prices and gives no investment advice.